logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals says cancer drug trial group has been expanded

Patients with late-stage colorectal cancer will be offered Faron drug Clevegen

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Oy (LON:FARN) (NASDAQ-FIRSTNORTH:FARON) shares rose on Monday as it said the data monitoring committee overseeing the phase I/II trial of its cancer drug has approved an expansion of the study into late-stage colorectal cancer.

The MATINS assessment is currently gauging safety and tolerability as well as the efficacy of its Clevegen treatment in people with melanoma, pancreatic, ovarian and colorectal cancer.

The drug, which can switch immune suppression to immune activation, will be administered in a low dose (0.3 milligrams per kilogram) in colorectal patients.

This dose, according to Faron, has been associated with “clinical response and has produced the strongest immune response”.

In a short update on progress, the company also revealed that all doses – 0.1mg/kg to 10mg/kg – had shown “good tolerability with no dose-limiting toxicity signals”.

“The decline in expression of negative immune checkpoint receptors post Clevegen dosing warrants expansion of Clevegen testing in numerous cancer types and therefore we will now ensure a rapid expansion of part II of the MATINS trial to continue investigating the safety and efficacy of Clevegen in various cancer cohort,” said Faron chief executive Markku Jalkanen.

Clevegen is being assessed both as a single therapy and in combination with other existing cancer treatments. With the ability to turn off immune suppression and activate an immune response, there could be applications beyond oncology, the firm reckons.

In late morning trading, Faron Pharma shares were 3.7% higher at 282.50p.

 -- Adds share price -- 

Quick facts: Faron Pharmaceuticals Ltd

Price: 247.5 GBX

AIM:FARN
Market: AIM
Market Cap: £107.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

on 12/12/19

2 min read